Metabolic Stability and Analogue-Based Drug Discovery

Analogue-Based Drug Discovery III

Volumn , Issue , 2012, Pages 37-75

  Kalgutkar, Amit S ^a   Stepan, Antonia F ^a  

^a PFIZER INC   (United States)

Author keywords

Clearance; Drug discovery; Drug drug interaction; Lead optimization; Metabolic stability; Pharmacokinetics; Reactive metabolite; Structure activity relationship

Indexed keywords

EID: 84885547682     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527651085.ch3     Document Type: Chapter

References (83)

1. Riley, R.J. (2001) The potentialpharmacological and toxicological impactof P450 screening. Curr. Opin. DrugDiscov. Dev., 4 (1), 45-54.
2. Pryde, D.C., Dalvie, D., Hu, Q., Jones, P.,Obach, R.S., and Tran, T.D. (2010)Aldehyde oxidase: an enzyme of emergingimportance in drug discovery. J. Med.Chem., 53 (24), 8441-8460.
3. Kalgutkar, A.S., Dalvie, D.K., Castagnoli,N., Jr., and Taylor, T.J. (2001) Interactionsof nitrogen-containing xenobiotics withmonoamine oxidase (MAO) isozymes Aand B: SAR studies on MAO substratesand inhibitors. Chem. Res. Toxicol., 14 (9),1139-1162.
4. Bu, H.Z. (2006) A literature review ofenzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113drugs in human liver microsomes:structure-kinetics relationshipassessment. Curr. Drug Metab., 7 (3),231-249.
5. Stepan, A.F., Karki, K., McDonald,W.S.,Dorff, P.H., Dutra, J.K., Dirico, K.J., Won,A., Subramanyam, C., Efremov, I.V.,O'Donnell, C.J., Nolan, C.E., Becker, S.L.,Pustilnik, L.R., Sneed, B., Sun, H., Lu, Y.,Robshaw, A.E., Riddell, D., O'Sullivan,T.J., Sibley, E., Capetta, S., Atchison, K.,Hallgren, A.J., Miller, E., Wood, A., andObach, R.S. (2011) Metabolism-directeddesign of oxetane-containingarylsulfonamide derivatives as c-secretaseinhibitors. J. Med. Chem., 54 (22),7772-7783.
6. Cheng, Y., Zhang, F., Rano, T.A., Lu, Z.,Scheif, W.A., Gabryelski, L., Olsen, D.B., Stahlhut, M., Rutkowski, C.A., Lin, J.H.,Jin, L., Emini, E.A., Chapman, K.T., andTata, J.R. (2002) Indinavir analogues withblocked metabolism sites as HIV proteaseinhibitors with improved pharmacologicalprofiles and high potency against PIresistantviral strains. Bioorg. Med. Chem.Lett., 12 (17), 2419-2422.
7. Floyd, D.M., Kimball, S.D., Krapcho, J.,Das, J., Turk, C.F., Moquin, R.V., Lago, M.W., Duff, K.J., Lee, V.G., White, R.E.,Ridgewell, R.E., Moreland, S., Brittain,R.J., Normandin, D.E., Hedberg, S.A., andCucinotta, G.C. (1992) Benzazepinonecalcium channel blockers. 2. Structure-activity and drug metabolism studiesleading to potent antihypertensive agents.Comparison with benzothiazepinones. J.Med. Chem., 35 (4), 756-772.
8. Park, B.K., Kitteringham, N.R., andO'Neill, P.M. (2001) Metabolism offluorine-containing drugs. Annu. Rev.Pharmacol. Toxicol., 41, 443-470.
9. Fisher, M.B., Henne, K.R., and Boer, J.(2006) The complexities inherent inattempts to decrease drug clearance byblocking sites of CYP-mediatedmetabolism. Curr. Opin. Drug Discov. Dev.,9 (1), 101-109.
10. Moorjani, M., Luo, Z., Lin, E., Vong, B.G.,Chen, Y., Zhang, X., Rueter, J.K., Gross,R.S., Lanier, M.C., Tellew, J.E., Williams,J.P., Lechner, S.M., Malany, S., Santos, M.,Crespo, M.I., Doaz, J.-L., Saunders, J., andSlee, D.H. (2008) 2,6-Diaryl-4-acylaminopyrimidines as potent andselective adenosine A2A antagonists withimproved solubility and metabolic stability. Bioorg. Med. Chem. Lett., 18 (20),5402-5405.
11. Eldrup, A.B., Soleymanzadeh, F., Taylor,S.J., Muegge, I., Farrow, N.A., Joseph, D.,McKellop, K., Man, C.C., Kukulka, A., andDe Lombaert, S. (2009) Structure-basedoptimization of arylamides as inhibitors ofsoluble epoxide hydrolase. J. Med. Chem.,52 (19), 5880-5895.
12. Burgey, C.S., Robinson, K.A., Lyle, T.A.,Sanderson, P.E.J., Lewis, S.D., Lucas, B.J.,Krueger, J.A., Singh, R., Miller-Stein, C.,White, R.A., Wong, B., Lyle, E.A.,Williams, P.D., Coburn, C.A., Dorsey, B.D., Barrow, J.C., Stranieri, M.T., Holahan,M.A., Sitko, G.R., Cook, J.J., McMasters,D.R., McDonough, C.M., Sanders,W.M.,Wallace, A.A., Clayton, F.C., Bohn, D.,Leonard, Y.M., Detwiler, T.J., Jr., Lynch,J.J., Jr., Yan, Y., Chen, Z., Kuo, L., Gardell,S.J., Shafer, J.A., and Vacca, J.P. (2003)Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombininhibitors. Development of an orallybioavailable series containing P1 and P3pyridines. J. Med. Chem., 46 (4), 461-473.
13. Dugar, S., Yumibe, N., Clader, J.W.,Vizziano, M., Huie, K., Van Heek, M.,Compton, D.S., and Davis, H.R., Jr. (1996)Metabolism and structure activity databased drug design: discovery of(-)-SCH53079, an analog of the potentcholesterol absorption inhibitor(-)-SCH48461. Bioorg. Med. Chem. Lett., 6(11), 1271-1274.
14. Kirkup, M.P., Rizvi, R., Shanker, B.B.,Dugar, S., Clader, J.W., McCombie, S.W.,Lin, S.-I., Yumibe, N., Huie, K., Van Heek,M., Compton, D.S., Davis, H.R., Jr., andMcPhail, A.T. (1996) (-)-SCH 57939:synthesis and pharmacological propertiesof a potent, metabolically stablecholesterol absorption inhibitor. Bioorg.Med. Chem. Lett., 6 (17), 2069-2072.
15. Rosenblum, S.B., Huynh, T., Afonso, A.,Davis, H.R., Jr., Yumibe, N., Clader, J.W.,and Burnett, D.A. (1998) Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH58235): a designed, potent, orally activeinhibitor of cholesterol absorption. J. Med.Chem., 41 (6), 973-980.
16. Penning, T.D., Talley, J.J., Bertenshaw,S.R., Carter, J.S., Collins, P.W., Docter, S.,Graneto, M.J., Lee, L.F., Malecha, J.W.,Rogers, R.S., Rogier, D.J., Yu, S.S.,Anderson, G.D., Burton, E.G., Cogburn,J.N., Gregory, S.A., Koboldt, C.M.,Perkins, W.E., Seibert, K., Veenhuizen, A.W., Zhang, Y.Y., and Isakson, P.C. (1997)Synthesis and biological evaluation of the1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J. Med. Chem., 40 (9),1347-1365.
17. Southers, J.A., Bauman, J.N., Price, D.A.,Humphries, P.S., Balan, G., Sagal, J.F.,Maurer, T.S., Zhang, Y., Oliver, R., Herr,M., Healy, D.R., Li, M., Kapinos, B., Fate,G.D., Riccardi, K.A., Paralkar, V.M.,Brown, T.A., and Kalgutkar, A.S. (2010)Metabolism-guided design of short-actingcalcium-sensing receptor antagonists.ACS Med. Chem. Lett., 1, 219-223.
18. Middleton, D.S., Andrews, M., Glossop,P., Gymer, G., Hepworth, D., Jessiman,A., Johnson, P.S., MacKenny, M., Stobie,A., Tang, K., Morgan, P., and Jones, B.(2008) Designing rapid onset selectiveserotonin re-uptake inhibitors. Part 3.Site-directed metabolism as a strategy toavoid active circulating metabolites:structure-activity relationships of(thioalkyl)phenoxy benzylamines. Bioorg.Med. Chem. Lett., 18 (19), 5303-5306.
19. Magee, T.V., Ripp, S.L., Li, B., Buzon,R.A., Chupak, L., Dougherty, T.J., Finegan,S.M., Girard, D., Hagen, A.E., Falcone,M.J., Farley, K.A., Granskog, K., Hardink,J.R., Huband, M.D., Kamicker, B.J.,Kaneko, T., Knickerbocker, M.J., Liras,J.L., Marra, A., Medina, I., Nguyen, T.T.,Noe, M.C., Obach, R.S., O'Donnell, J.P.,Penzien, J.B., Reilly, U.D., Schafer, J.R.,Shen, Y., Stone, G.G., Strelevitz, T.J., Sun,J., Tait-Kamradt, A., Vaz, A.D., Whipple,D.A., Widlicka, D.W., Wishka, D.G.,Wolkowski, J.P., and Flanagan, M.E.(2009) Discovery of azetidinyl ketolides forthe treatment of susceptible andmultidrug resistant community-acquiredrespiratory tract infections. J. Med. Chem.,52 (23), 7446-7457.
20. Linton, A., Kang, P., Ornelas, M., Kephart,S., Hu, Q., Pairish, M., Jiang, Y., and Guo,C. (2011) Systematic structuremodifications of imidazo[1,2-a]pyrimidineto reduce metabolism mediated byaldehyde oxidase (AO). J. Med. Chem., 54(21), 7705-7712.
21. Dixon, C.M., Park, G.R., and Tarbit, M.H.(1994) Characterization of the enzymeresponsible for the metabolism ofsumatriptan in human liver. Biochem.Pharmacol., 47 (7), 1253-1257.
22. McEnroe, J.D., and Fleishaker, J.C. (2005)Clinical pharmacokinetics of almotriptan,a serotonin 5-HT(1B/1D) receptor agonistfor the treatment of migraine. Clin.Pharmacokinet., 44 (3), 237-246.
23. Vyas, K.P., Halpin, R.A., Geer, L.A., Ellis,J.D., Liu, L., Cheng, H., Chavez-Eng, C.,Matuszewski, B.K., Varga, S.L., Guiblin,A.R., and Rogers, J.D. (2000) Dispositionand pharmacokinetics of the antimigrainedrug, rizatriptan, in humans. Drug Metab.Dispos., 28 (1), 89-95.
24. Wild, M.J., McKillop, D., and Butters, C.J.(1999) Determination of the humancytochrome P450 isoforms involved in themetabolism of zolmitriptan. Xenobiotica,29 (8), 847-857.
25. Evans, D.C., O'Conner, D., Lake, B.G.,Evers, R., Allen, C., and Hargreaves, R.(2003) Eletriptan metabolism by humanhepatic CYP450 enzymes and transport byhuman P-glycoprotein. Drug Metab.Dispos., 31 (7), 861-869.
26. Buchan, P., Keywood, C., Wade, A., andWard, C. (2002) Clinical pharmacokineticsof frovatriptan. Headache, 42 (Suppl. 2),S54-S62.
27. Tfelt-Hansen, P., De Vries, P., and Saxena,P.R. (2000) Triptans in migraine: acomparative review of pharmacology,pharmacokinetics and efficacy. Drugs, 60(6), 1259-1287.
28. Fisher, M.B., Paine, M.F., Strelevitz, T.J.,and Wrighton, S.A. (2001) The role ofhepatic and extrahepatic UDPglucuronosyltransferasesin human drugmetabolism. Drug Metab. Rev., 33 (3-4),273-297.
29. Lindsay, J., Wang, L.L., Li, Y., and Zhou,S.F. (2008) Structure, function andpolymorphism of human cytosolic sulfotransferases. Curr. Drug Metab., 9 (2),99-105.
30. Honma,W., Shimada, M., Sasano, H.,Ozawa, S., Miyata, M., Nagata, K., Ikeda,T., and Yamazoe, Y. (2002) Phenolsulfotransferase, ST1A3, as the mainenzyme catalyzing sulfation oftroglitazone in human liver. Drug Metab.Dispos., 30 (8), 944-949.
31. Borzilleri, R.M., Cai, Z.W., Ellis, C.,Fargnoli, J., Fura, A., Gerhardt, T., Goyal,B., Hunt, J.T., Mortillo, S., Qian, L.,Tokarski, J., Vyas, V., Wautlet, B., Zheng,X., and Bhide, R.S. (2005) Synthesis andSAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f ][1,2,4]triazine based VEGFR-2kinase inhibitors. Bioorg. Med. Chem. Lett.,15 (5), 1429-1433.
32. Stewart, A.O., Bhatia, P.A., Martin, J.G.,Summers, J.B., Rodriques, K.E., Martin,M.B., Holms, J.H., Moore, J.L., Craig, R.A., Kolasa, T., Ratajczyk, J.D., Mazdiyasni,H., Kerdesky, F.A., DeNinno, S.L., Maki,R.G., Bouska, J.B., Young, P.R., Lanni, C.,Bell, R.L., Carter, G.W., and Brooks, C.D.(1997) Structure-activity relationships ofN-hydroxyurea 5-lipoxygenase inhibitors.J. Med. Chem., 40 (13), 1955-1968.
33. Awni, W.M., Braeckman, R.A.,Granneman, G.R., Witt, G., and Dube,L.M. (1995) Pharmacokinetics andpharmacodynamics of zileuton after oraladministration of single and multipledose regimens of zileuton 600 mg inhealthy volunteers. Clin. Pharmacokinet.,29 (Suppl. 2), 22-33.
34. Dobo, K.L., Obach, R.S., Luffer-Atlas, D.,and Bercu, J.P. (2009) A strategy for therisk assessment of human genotoxicmetabolites. Chem. Res. Toxicol., 22 (2),348-356.
35. Kalgutkar, A.S., Obach, R.S., and Maurer,T.S. (2007) Mechanism-based inactivationof cytochrome P450 enzymes: chemicalmechanisms, structure-activityrelationships and relationship to clinicaldrug-drug interactions and idiosyncraticadverse drug reactions. Curr. Drug Metab.,8 (5), 407-447.
36. Stepan, A.F.,Walker, D.P., Bauman, J.,Price, D.A., Baillie, T.A., Kalgutkar, A.S.,and Aleo, M.D. (2011) Structuralalert/reactive metabolite concept as applied in medicinal chemistry to mitigatethe risk of idiosyncratic drug toxicity: aperspective based on the criticalexamination of trends in the top 200 drugsmarketed in the United States. Chem. Res.Toxicol., 24 (9), 1345-1410.
37. Park, B.K., Boobis, A., Clarke, S.,Goldring, C.E., Jones, D., Kenna, J.G.,Lambert, C., Laverty, H.G., Naisbitt, D.J.,Nelson, S., Nicoll-Griffith, D.A., Obach, R.S., Routledge, P., Smith, D.A., Tweedie, D.J., Vermeulen, N., Williams, D.P., Wilson,I.D., and Baillie, T.A. (2011) Managing thechallenge of chemical reactive metabolitesin drug development. Nat. Rev. DrugDiscov., 10 (4), 292-306.
38. Kumar, S., Kassahun, K., Tschirret-Guth,R.A., Mitra, K., and Baillie, T.A. (2008)Minimizing metabolic activation duringpharmaceutical lead optimization:progress, knowledge gaps and futuredirections. Curr. Opin. Drug Discov. Dev.,11 (1), 43-52.
39. Guengerich, F.P. and MacDonald, J.S.(2007) Applying mechanisms of chemicaltoxicity to predict drug safety. Chem. Res.Toxicol., 20 (3), 344-369.
40. Kalgutkar, A.S., Dalvie, D.K., Aubrecht, J.,Smith, E.B., Coffing, S.L., Cheung, J.R.,Vage, C., Lame, M.E., Chiang, P.,McClure, K.F., Maurer, T.S., Coelho, R.V.,Jr., Soliman, V.F., and Schildknegt, K.(2007) Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine,a novel 5-hydroxytryptamine 2C receptoragonist for the treatment of obesity: role ofmetabolic activation. Drug Metab. Dispos.,35 (6), 848-858.
41. Kalgutkar, A.S., Bauman, J.N., McClure,K.F., Aubrecht, J., Cortina, S.R., andParalkar, J. (2009) Biochemical basis fordifferences in metabolism-dependentgenotoxicity by two diazinylpiperazinebased5-HT2C receptor agonists. Bioorg.Med. Chem. Lett., 19 (6), 1559-1563.
42. Lim, H.-K., Chen, J., Sensenhauser, C.,Cook, K., Preston, R., Thomas, T., Shook,B., Jackson, P.F., Rassnick, S., Rhodes, K.,Gopaul, V., Salter, R., Silva, J., and Evans,D.C. (2011) Overcoming the genotoxicityof a pyrrolidine substitutedarylindenopyrimidine as a potent dualadenosine A2A/A1 antagonist by minimizing bioactivation to an iminiumion reactive intermediate. Chem. Res.Toxicol., 24 (7), 1012-1030.
43. Bertelsen, K.M., Venkatakrishnan, K., VonMoltke, L.L., Obach, R.S., and Greenblatt,D.J. (2003) Apparent mechanism-basedinhibition of human CYP2D6 in vitro byparoxetine: comparison with fluoxetineand quinidine. Drug Metab. Dispos., 31 (3),289-293.
44. Murray, M. (2000) Mechanisms ofinhibitory and regulatory effects ofmethylenedioxyphenyl compounds oncytochrome P450-dependent drugoxidation. Curr. Drug Metab., 1 (1), 67-84.
45. Haddock, R.E., Johnson, A.M., Langley, P.F., Nelson, D.R., Pope, J.A., Thomas, D.R., and Woods, F.R. (1989) Metabolicpathways of paroxetine in animals andman and the comparative pharmacologicalproperties of its metabolites. ActaPsychiatr. Scand. Suppl., 350, 24-26.
46. Zhao, S.X., Dalvie, D.K., Kelly, J.M.,Soglia, J.R., Frederick, K.S., Smith, E.B.,Obach, R.S., and Kalgutkar, A.S. (2007)NADPH-dependent covalent binding of[3H]paroxetine to human livermicrosomes and S-9 fractions:identification of an electrophilic quinonemetabolite of paroxetine. Chem. Res.Toxicol., 20 (11), 1649-1657.
47. Kaye, C.M., Haddock, R.E., Langley, P.F.,Mellows, G., Tasker, T.C., Zussman, B.D.,and Greb, W.H. (1989) A review of themetabolism and pharmacokinetics ofparoxetine in man. Acta Psychiatr. Scand.Suppl., 350, 60-75.
48. Hemeryck, A., Lefebyre, R.A., De Vriendt,C., and Belpaire, F.M. (2000) Paroxetineaffects metoprolol pharmacokinetics andpharmacodynamics in healthy volunteers.Clin. Pharmacol. Ther., 67 (3), 283-291.
49. Spina, E., Avenoso, A., Facciola, G.,Scordo, M.G., Ancione, M., and Madia, A.(2001) Plasma concentrations ofrisperidone and 9-hydroxyrisperidoneduring combined treatment withparoxetine. Ther. Drug Monit., 23 (3),223-227.
50. Belle, D.J., Ernest, C.S., Sauer, J.M.,Smith, B.P., Thomasson, H.R., andWitcher, J.W. (2002) Effect of potentCYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J. Clin.Pharmacol., 42 (11), 1219-1227.
51. Yarnell, A.T. (2009) Heavy-hydrogen drugsturn heads, again. Chem. Eng. News, 87(25), 36-39.
52. Wendt, M.K., and Schiemann, W.P. (2009)Therapeutic targeting of the focaladhesion complex prevents oncogenicTGF-beta signaling and metastasis. BreastCancer Res., 11 (5), R68.
53. Walker, D.P., Bi, F.C., Kalgutkar, A.S.,Bauman, J.N., Zhao, S.X., Soglia, J.R.,Aspnes, G.E., Kung, D.W., Klug-McLeod, J., Zawistoski, M.P., McGlynn,M.A., Oliver, R., Dunn, M., Li, J.C.,Richter, D.T., Cooper, B.A., Kath, J.C.,Hulford, C.A., Autry, C.L., Luzzio, M.J.,Ung, E.J., Roberts, W.G., Bonnette,P.C., Buckbinder, L., Mistry, A., Griffor,M.C., Han, S., and Guzman-Perez, A.(2008) Trifluoromethylpyrimidine-basedinhibitors of proline-rich tyrosinekinase 2 (PYK2): structure-activityrelationships and strategies for theelimination of reactive metaboliteformation. Bioorg. Med. Chem. Lett., 18(23), 6071-6077.
54. Bakshi, R.K., Hong, Q., Olson, J.T., Ye, Z.,Sebhat, I.K.,Weinberg, D.H., MacNeil, T.,Kalyani, R.N., Tang, R., Martin, W.J.,Strack, A., McGowan, E., Tamvakopoulos,C., Miller, R.R., Stearns, R.A., Tang, W.,MacIntyre, D.E., van der Ploeg, L.H.T.,Patchett, A.A., and Nargund, R.P. (2005)1-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid as a Tic mimetic:application in the synthesis of potenthuman melanocortin-4 receptor selectiveagonists. Bioorg. Med. Chem. Lett., 15 (14),3430-3433.
55. Tang, W., Stearns, R.A., Wang, R.W.,Miller, R.R., Chen, Q., Ngui, J., Bakshi, R.K., Nargund, R.P., Dean, D.C., and Baillie,T.A. (2008) Assessing and minimizingtime-dependent inhibition of cytochromeP450 3A in drug discovery: a case studywith melanocortin-4 receptor agonists.Xenobiotica, 38 (11), 1437-1451.
56. Teffera, Y., Colletti, A.E., Harmange, J.C.,Hollis, L.S., Albrecht, B.K., Boezio, A.A.,Liu, J., and Zhao, Z. (2008) Chemicalreactivity of methoxy 4-o-aryl quinolines:identification of glutathione displacement products in vitro and in vivo. Chem. Res.Toxicol., 21 (11), 2216-2222.
57. Pfefferkorn, J.A., Lou, J., Minich, M.L.,Filipski, K.J., He, M., Zhou, R., Ahmed,S., Benbow, J., Perez, A.G., Tu, M.,Litchfield, J., Sharma, R., Metzler, K.,Bourbonais, F., Huang, C., Beebe, D.A.,and Oates, P.J. (2009) Pyridones asglucokinase activators: identification of aunique metabolic liability of the4-sulfonyl-2-pyridone heterocycle. Bioorg.Med. Chem. Lett., 19 (12), 3247-3252.
58. Litchfield, J., Sharma, R., Atkinson, K.,Filipski, K.J., Wright, S.W., Pfefferkorn, J.A., Tan, B., Kosa, R.E., Stevens, B., Tu, M.,and Kalgutkar, A.S. (2010) Intrinsicelectrophilicity of the 4-methylsulfonyl-2-pyridone scaffold in glucokinaseactivators: role of glutathione-Stransferasesand in vivo quantitation of aglutathione conjugate in rats. Bioorg. Med.Chem. Lett., 20 (21), 6262-6267.
59. Pfefferkorn, J.A., Guzman-Perez, A.,Oates, P.J., Litchfield, J., Aspnes, G.,Basak, A., Benbow, J., Berliner, M.A.,Bian, J., Choi, C., Freeman-Cook, K.,Corbett, J.W., Didiuk, M., Dunetz, J.R.,Filipski, K.J., Hungerford,W.M., Jones,C.S., Karki, K., Ling, A., Li, J.-C., Patel, L.,Perreault, C., Risley, H., Saenz, J., Song,W., Tu, M., Aiello, R., Atkinson, K.,Barucci, N., Beebe, D., Bourassa, P.,Bourbounais, F., Brodeur, A.M., Burbey,R., Chen, J., D'Aquila, T., Derksen, D.R.,Haddish-Berhane, N., Huang, C., Landro,J., Lapworth, A.L., MacDougall, M.,Perregaux, D., Pettersen, J., Robertson, A.,Tan, B., Treadway, J.L., Liu, S., Qiu, X.,Knafels, J., Ammirati, M., Song, X.,DaSilva-Jardine, P., Liras, S., Sweet, L.,and Rolph, T.P. (2011) Designingglucokinase activators with reducedhypoglycemia risk: discovery of N,Ndimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinicalcandidate for the treatment of type 2diabetes mellitus. Med. Chem. Commun.,2, 828-839.
60. Liu, Z.X., and Kaplowitz, N. (2006) Role ofinnate immunity in acetaminopheninducedhepatotoxicity. Expert Opin. DrugMetab. Toxicol., 2 (4), 493-503.
61. Dahlin, D.C., Miwa, G.T., Lu, A.Y., andNelson, S.D. (1984) N-Acetyl-pbenzoquinoneimine: a cytochrome P-450-mediated oxidation product ofacetaminophen. Proc. Natl. Acad. Sci.USA, 81 (5), 1327-1331.
62. Kalgutkar, A.S., and Didiuk, M.T. (2009)Structural alerts, reactive metabolites, andprotein covalent binding: how reliable arethese attributes as predictors of drugtoxicity. Chem. Biodivers., 6 (11),2115-2137.
63. Uetrecht, J.P. (1992) Metabolism ofclozapine by neutrophils. Possibleimplications for clozapine-inducedagranulocytosis. Drug Saf., 7 (Suppl. 1),51-56.
64. Gardner, I., Leeder, J.S., Chin, T., Zahid,N., and Uetrecht, J.P. (1998) Acomparison of the covalent binding ofclozapine and olanzapine to humanneutrophils in vitro and in vivo. Mol.Pharmacol., 53 (6), 999-1008.
65. Uetrecht, J., Zahid, N., Tehim, A., Fu, J.M.,and Rakhit, S. (1997) Structural featuresassociated with reactive metaboliteformation with clozapine analogues. Chem.Biol. Interact., 104 (2-3), 117-129.
66. Obach, R.S., Kalgutkar, A.S., Ryder, T.F.,and Walker, G.S. (2008) In vitrometabolism and covalent binding of enolcarboxamidederivatives and antiinflammatoryagents sudoxicam andmeloxicam: insights into thehepatotoxicity of sudoxicam. Chem. Res.Toxicol., 21 (9), 1890-1899.
67. Hartz, R.A., Ahuja, V.T., Zhuo, X.,Mattson, R.J., Denhart, D.J., Deskus, J.A.,Vrudhula, V.M., Pan, S., Ditta, J.L., Shu, Y.Z., Grace, J.E., Lentz, K.A., Lelas, S., Li, Y.W., Molski, T.F., Krishnananthan, S.,Wong, H., Qian-Cutrone, J., Schartman,R., Denton, R., Lodge, N.J., Zaczek, R.,Macor, J.E., and Bronson, J.J. (2009) Astrategy to minimize reactive metaboliteformation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailablecorticotropin-releasing factor-1 receptorantagonist. J. Med. Chem., 52 (23),7653-7668.
68. Zhuo, X., Hartz, R.A., Bronson, J.J.,Wong, H., Ahuja, V.T., Vrudhula, V.M.,Leet, J.E., Huang, S., Macor, J.E., and Shu,Y.Z. (2010) Comparativebiotransformation of pyrazinonecontainingcorticotropin-releasing factorreceptor-1 antagonists: minimizing thereactive metabolite formation. DrugMetab. Dispos., 38 (1), 5-15.
69. Kalgutkar, A.S., Driscoll, J., Zhao, S.X.,Walker, G.S., Shepard, R.M., Soglia, J.R.,Atherton, J., Yu, Li., Mutlib, A.E.,Munchhof, M.J., Reiter, L.A., Jones, C.S.,Doty, J.L., Trevena, K.A., Shaffer, C.L., andRipp, S.L. (2007) A rational chemicalintervention strategy to circumventbioactivation liabilities associated with anonpeptidyl thrombopoietin receptoragonist containing a 2-amino-4-arylthiazole motif. Chem. Res. Toxicol., 20(12), 1954-1965.
70. Antipas, A.S., Blumberg, L.C., Brissette,W.H., Brown, M.F., Casavant, J.M., Doty,J.L., Driscoll, J., Harris, T.M., Jones, C.S.,McCurdy, S.P., McElroy, E., Mitton-Fry,M., Munchhof, M.J., Reim, D.A., Reiter, L.A., Ripp, S.L., Shavnya, A., Smeets, M.I.,and Trevena, K.A. (2010) Structure-activity relationships and hepatic safetyrisks of thiazole agonists of thethrombopoietin receptor. Bioorg. Med.Chem. Lett., 20 (14), 4069-4072.
71. Tingle, M.D., Jewell, H., Maggs, J.L.,O'Neill, P.M., and Park, B.K. (1995) Thebioactivation of amodiaquine by humanpolymorphonuclear leucocytes in vitro:chemical mechanisms and the effects offluorine substitution. Biochem.Pharmacol., 50 (7), 1113-1119.
72. Maggs, J.L., Tingle, M.D., Kitteringham,N.R., and Park, B.K. (1988) Drug-proteinconjugates. 14. Mechanisms of formationof protein-arylating intermediates fromamodiaquine, a myelotoxin andhepatotoxin in man. Biochem. Pharmacol.,37 (2), 303-311.
73. Tingle, M.D., Jewell, H., Maggs, J.L.,O'Neill, P.M., and Park, B.K. (1995) Thebioactivation of amodiaquine by humanpolymorphonuclear leucocytes in vitro:chemical mechanisms and the effects offluorine substitution. Biochem.Pharmacol., 50 (7), 1113-1119.
74. O'Neill, P.M., Harrison, A.C., Storr, R.C.,Hawley, S.R., Ward, S.A., and Park, B.K.(1994) The effect of fluorine substitutionon the metabolism and antimalarialactivity of amodiaquine. J. Med. Chem., 37(9), 1362-1370.
75. O'Neill, P.M., Shone, A.E., Stanford, D.,Nixon, G., Asadollahy, E., Park, B.K.,Maggs, J.L., Roberts, P., Stocks, P.A.,Biagini, G., Bray, P.G., Davies, J., Berry,N., Hall, C., Rimmer, K., Winstanley, P.A.,Hindley, S., Bambal, R.B., Davis, C.B.,Bates, M., Gresham, S.L., Brigandi, R.A.,Gomez-de-Las-Heras, F.M., Gargallo, D.V., Parapini, S., Vivas, L., Lander, H.,Taramelli, D., and Ward, S.A. (2009)Synthesis, antimalarial activity, andpreclinical pharmacology of a novel seriesof 40-fluoro and 40-chloro analogues ofamodiaquine. Identification of a suitable"back-up" compound for N-tert-butylisoquine. J. Med. Chem., 52 (7), 1828-1844.
76. O'Neill, P.M., Park, B.K., Shone, A.E.,Maggs, J.L., Roberts, P., Stocks, P.A.,Biagini, G.A., Bray, P.G., Gibbons, P.,Berry, N., Winstanley, P.A., Mukhtar, A.,Bonar-Law, R., Hindley, S., Bambal, R.B.,Davis, C.B., Bates, M., Hart, T.K.,Gresham, S.L., Lawrence, R.M., Brigandi,R.A., Gomez-delas-Heras, F.M., Gargallo,D.V., and Ward, S.A. (2009) Candidateselection and preclinical evaluation ofN-tert-butyl isoquine (GSK369796), anaffordable and effective 4-aminoquinolineantimalarial for the 21st century. J. Med.Chem., 52 (5), 1408-1415.
77. Hagmann,W.K. (2008) The discovery oftaranabant, a selective cannabinoid-1receptor inverse agonist for the treatmentof obesity. Arch. Pharm., 341, 405-411.
78. Nightingale, S.L. (1994) Recommendationto immediately withdraw patients fromtreatment with felbamate. J. Am. Med.Assoc., 272 (13), 995.
79. Thompson, C.D., Kinter, M.T., andMacdonald, T.L. (1996) Synthesis and invitro reactivity of 3-carbamoyl-2-phenylpropionaldeyde and 2-phenylpropenal: putative reactivemetabolites of felbamate. Chem. Res.Toxicol., 9 (8), 1225-1229.
80. Diekhaus, C.M., Thompson, C.D., Roller,S.G., and MacDonald, T.L. (2002)Mechanisms of idiosyncratic drugreactions: the case of felbamate. Chem.Biol. Interact., 142 (1-2), 99-117.
81. Thompson, C.D., Barthen, M.T., Hopper,D.W., Miller, T.A., Quigg, M., Hudspeth,C., Montouris, G., Marsh, L., Perhach, J.L., Sofia, R.D., and Macdonald, T.L. (1999)Quantitation in patient urine samples offelbamate and three metabolites: acidcarbamate and two mercapturic acids.Epilepsia, 40 (6), 769-776.
82. Roecklein, B.A., Sacks, H.J., Mortko, H.,and Stables, J. (2007) Fluorofelbamate.Neurotherapeutics, 4 (1), 97-101.
83. Smith, D.A., Allerton, C., Kalgutkar, A.,van deWaterbeemd, H., and Walker, D.K.(2012) Pharmacokinetics and Metabolism inDrug Design, 3rd edn, Wiley-VCH VerlagGmbH,Weinheim.